Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 19/20 | 0.71 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.61 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782484 | 1.00 | PTPN1 (0.71) | PTPN1PTPN2PTPN11MAOB | |
| SCHEMBL4152816 | 0.89 | PTPN1 (0.61) | PTPN1PTPN2PTPN11 | |
| SCHEMBL13012004 | 0.84 | PTPN1 (0.73) | PTPN1PTPN2PTPN11 | |
| SCHEMBL14244758 | 0.83 | PTPN1 (0.71) | PTPN1PTPN2PTPN11MAOB | |
| SCHEMBL12425743 | 0.83 | PTPN1 (0.71) | PTPN1PTPN2PTPN11MAOB | |
| SCHEMBL1240288 | 0.83 | PTPN1 (0.71) | PTPN1PTPN2PTPN11 | |
| SCHEMBL4975794 | 0.82 | PTPN1 (0.70) | PTPN1PTPN2PTPN11 | |
| SCHEMBL952477 | 0.82 | PTPN1 (0.70) | PTPN1PTPN2PTPN11 | |
| SCHEMBL1239683 | 0.81 | PTPN1 (0.79) | PTPN1PTPN2PTPN11 | |
| SCHEMBL12426122 | 0.81 | PTPN1 (0.79) | PTPN1PTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | PTPN1 3225/4885PTPN2 4152/4885PTPN11 3779/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | PTPN1 3378/4885PTPN2 4112/4885PTPN11 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.